[Skip to Content]
[Skip to Content Landing]

Association of Blood Pressure Lowering With Mortality and Cardiovascular Disease Across Blood Pressure LevelsA Systematic Review and Meta-analysis

Educational Objective
To assess the association between blood pressure–lowering treatment and death and cardiovascular disease at different blood pressure levels.
1 Credit CME
Key Points

Question  What is the association between treatment to lower blood pressure and death and cardiovascular disease at different blood pressure levels?

Findings  In this systematic review and meta-analysis, including 74 trials and more than 300 000 patients, treatment to lower blood pressure was associated with a reduced risk for death and cardiovascular disease if baseline systolic blood pressure was 140 mm Hg or above. Below 140 mm Hg, the treatment effect was neutral in primary preventive trials, but with possible benefit on nonfatal cardiovascular events in trials of patients with coronary heart disease.

Meaning  Systolic blood pressure of 140 mm Hg or higher should be treated to prevent death and cardiovascular disease, whereas treatment may be considered in patients with coronary heart disease and systolic blood pressure below 140 mm Hg, but not for primary prevention.

Abstract

Importance  High blood pressure (BP) is the most important risk factor for death and cardiovascular disease (CVD) worldwide. The optimal cutoff for treatment of high BP is debated.

Objective  To assess the association between BP lowering treatment and death and CVD at different BP levels.

Data Sources  Previous systematic reviews were identified from PubMed, the Cochrane Database of Systematic Reviews, and the Database of Abstracts of Reviews of Effect. Reference lists of these reviews were searched for randomized clinical trials. Randomized clinical trials published after November 1, 2015, were also searched for in PubMed and the Cochrane Central Register for Controlled Trials during February 2017.

Study Selection  Randomized clinical trials with at least 1000 patient-years of follow-up, comparing BP-lowering drugs vs placebo or different BP goals were included.

Data Extraction and Synthesis  Data were extracted from original publications. Risk of bias was assessed using the Cochrane Collaborations assessment tool. Relative risks (RRs) were pooled in random-effects meta-analyses with Knapp-Hartung modification. Results are reported according to PRISMA guidelines.

Main Outcomes and Measures  Prespecified outcomes of interest were all-cause mortality, cardiovascular mortality, major cardiovascular events, coronary heart disease (CHD), stroke, heart failure, and end-stage renal disease.

Results  Seventy-four unique trials, representing 306 273 unique participants (39.9% women and 60.1% men; mean age, 63.6 years) and 1.2 million person-years, were included in the meta-analyses. In primary prevention, the association of BP-lowering treatment with major cardiovascular events was dependent on baseline systolic BP (SBP). In trials with baseline SBP 160 mm Hg or above, treatment was associated with reduced risk for death (RR, 0.93; 95% CI, 0.87-1.00) and a substantial reduction of major cardiovascular events (RR, 0.78; 95% CI, 0.70-0.87). If baseline SBP ranged from 140 to 159 mm Hg, the association of treatment with mortality was similar (RR, 0.87; 95% CI, 0.75-1.00), but the association with major cardiovascular events was less pronounced (RR, 0.88; 95% CI, 0.80-0.96). In trials with baseline SBP below 140 mm Hg, treatment was not associated with mortality (RR, 0.98; 95% CI, 0.90-1.06) and major cardiovascular events (RR, 0.97; 95% CI, 0.90-1.04). In trials including people with previous CHD and mean baseline SBP of 138 mm Hg, treatment was associated with reduced risk for major cardiovascular events (RR, 0.90; 95% CI, 0.84-0.97), but was not associated with survival (RR, 0.98; 95% CI, 0.89-1.07).

Conclusions and Relevance  Primary preventive BP lowering is associated with reduced risk for death and CVD if baseline SBP is 140 mm Hg or higher. At lower BP levels, treatment is not associated with any benefit in primary prevention but might offer additional protection in patients with CHD.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ from JAMA Network is your new home for CME and MOC from a source you trust. Earn AMA PRA Category 1 CME Credit™ from relevant articles, audio, and Clinical Challenge image quizzes, explore interactives and videos, and – depending on your specialty or state – have your MOC points automatically transferred to the relevant board. Learn more about CME

Article Information

Corresponding Author: Mattias Brunström, MD, Department Public Health and Clinical Medicine, Umeå University, Mail Code 901 87- SE, Umeå, Sweden (mattias.brunstrom@umu.se).

Accepted for Publication: August 31, 2017.

Correction: This article was corrected on January 2, 2018, to include links to an Invited Commentary.

Published Online: November 13, 2017. doi:10.1001/jamainternmed.2017.6015

Authors Contributions: Both authors had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis

Study concept and design: Both authors.

Acquisition, analysis, or interpretation of data: Both authors.

Drafting of the manuscript: Both authors.

Critical revision of the manuscript for important intellectual content: Both authors.

Statistical analysis: Both authors.

Obtained funding: Both authors.

Study supervision: Carlberg.

Conflict of Interest Disclosures: None reported.

Funding/Support: This study was supported by the Avtal om Läkarutbildning och medicinsk Forskning (ALF) agreement (for medical education and research) from Västerbotten County Council; by Visare Norr, an industry-independent fund supporting regional collaboration between County Councils in Northern Sweden; and by Norrländska Hjärtfonden.

Role of the Funder/Sponsor: The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

References
1.
Lim  SS, Vos  T, Flaxman  AD,  et al.  A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.  Lancet. 2012;380(9859):2224-2260.PubMedGoogle ScholarCrossref
2.
Weber  MA, Schiffrin  EL, White  WB,  et al.  Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension.  J Hypertens. 2014;32(1):3-15.PubMedGoogle ScholarCrossref
3.
Mancia  G, Fagard  R, Narkiewicz  K,  et al; Task Force Members.  2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).  J Hypertens. 2013;31(7):1281-1357.PubMedGoogle ScholarCrossref
4.
James  PA, Oparil  S, Carter  BL,  et al.  2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).  JAMA. 2014;311(5):507-520.PubMedGoogle ScholarCrossref
5.
Wright  JT  Jr, Williamson  JD, Whelton  PK,  et al; SPRINT Research Group.  A randomized trial of intensive versus standard blood-pressure control.  N Engl J Med. 2015;373(22):2103-2116.PubMedGoogle ScholarCrossref
6.
Ettehad  D, Emdin  CA, Kiran  A,  et al.  Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis.  Lancet. 2016;387(10022):957-967.PubMedGoogle ScholarCrossref
7.
Perkovic  V, Rodgers  A.  Redefining blood-pressure targets–SPRINT starts the marathon.  N Engl J Med. 2015;373(22):2175-2178.PubMedGoogle ScholarCrossref
8.
Laurent  S, Boutouyrie  P.  Blood pressure lowering trials: wrapping up the topic?  Lancet. 2016;387(10022):923-924.PubMedGoogle ScholarCrossref
9.
Brunström  M, Carlberg  B.  Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses.  BMJ. 2016;352:i717. PubMedGoogle ScholarCrossref
10.
Kjeldsen  SE, Lund-Johansen  P, Nilsson  PM, Mancia  G.  Unattended blood pressure measurements in the systolic blood pressure intervention trial: implications for entry and achieved blood pressure values compared with other trials.  Hypertension. 2016;67(5):808-812.PubMedGoogle ScholarCrossref
11.
Filipovský  J, Seidlerová  J, Kratochvíl  Z, Karnosová  P, Hronová  M, Mayer  O  Jr.  Automated compared to manual office blood pressure and to home blood pressure in hypertensive patients.  Blood Press. 2016;25(4):228-234.PubMedGoogle ScholarCrossref
12.
Brunström  M, Carlberg  B.  Standardization according to blood pressure lowering in meta-analyses of antihypertensive trials: comparison of three methodological approaches.  J Hypertens. doi:10.1097/HJH.0000000000001574Google Scholar
13.
Thomopoulos  C, Parati  G, Zanchetti  A.  Effects of blood pressure lowering on outcome incidence in hypertension, 4: effects of various classes of antihypertensive drugs–overview and meta-analyses.  J Hypertens. 2015;33(2):195-211.PubMedGoogle ScholarCrossref
14.
McMurray  JJV, Adamopoulos  S, Anker  SD,  et al; ESC Committee for Practice Guidelines.  ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology, developed in collaboration with the Heart Failure Association (HFA) of the ESC.  Eur Heart J. 2012;33(14):1787-1847.PubMedGoogle ScholarCrossref
15.
Law  MR, Morris  JK, Wald  NJ.  Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies.  BMJ. 2009;338:b1665.PubMedGoogle ScholarCrossref
16.
Higgins  JPT, Altman  DG, Gøtzsche  PC,  et al; Cochrane Bias Methods Group; Cochrane Statistical Methods Group.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials.  BMJ. 2011;343:d5928.PubMedGoogle ScholarCrossref
17.
Amery  A, Birkenhäger  W, Brixko  P,  et al.  Mortality and morbidity results from the European Working Party on High Blood-Pressure in the Elderly trial.  Lancet. 1985;1(8442):1349-1354.PubMedGoogle ScholarCrossref
18.
Black  HR, ed.  Clinical Trials in Hypertension. New York, NY: Marcel Dekker Inc; 2001.
19.
Poole-Wilson  PA, Lubsen  J, Kirwan  BA,  et al; Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system investigators.  Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial.  Lancet. 2004;364(9437):849-857.PubMedGoogle ScholarCrossref
20.
Nissen  SE, Tuzcu  EM, Libby  P,  et al; CAMELOT Investigators.  Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial.  JAMA. 2004;292(18):2217-2225.PubMedGoogle ScholarCrossref
21.
Fox  KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators.  Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).  Lancet. 2003;362(9386):782-788.PubMedGoogle ScholarCrossref
22.
Yusuf  S, Sleight  P, Pogue  J, Bosch  J, Davies  R, Dagenais  G; Heart Outcomes Prevention Evaluation Study Investigators.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.  N Engl J Med. 2000;342(3):145-153.PubMedGoogle ScholarCrossref
23.
Yusuf  S, Teo  KK, Pogue  J,  et al; ONTARGET Investigators.  Telmisartan, ramipril, or both in patients at high risk for vascular events.  N Engl J Med. 2008;358(15):1547-1559.PubMedGoogle ScholarCrossref
24.
Braunwald  E, Domanski  MJ, Fowler  SE,  et al; PEACE Trial Investigators.  Angiotensin-converting-enzyme inhibition in stable coronary artery disease.  N Engl J Med. 2004;351(20):2058-2068.PubMedGoogle ScholarCrossref
25.
Pitt  B, Byington  RP, Furberg  CD,  et al; PREVENT Investigators.  Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events.  Circulation. 2000;102(13):1503-1510.PubMedGoogle ScholarCrossref
26.
Teo  KK, Burton  JR, Buller  CE,  et al.  Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT).  Circulation. 2000;102(15):1748-1754.PubMedGoogle ScholarCrossref
27.
Yusuf  S, Teo  K, Anderson  C,  et al; Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators.  Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.  Lancet. 2008;372(9644):1174-1183.PubMedGoogle ScholarCrossref
28.
The Dutch TIA Trial Study Group.  Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke.  Stroke. 1993;24(4):543-548.PubMedGoogle ScholarCrossref
29.
Hypertension-Stroke Cooperative Study Group.  Effect of antihypertensive treatment on stroke recurrence.  JAMA. 1974;229(4):409-418.PubMedGoogle ScholarCrossref
30.
Yusuf  S, Diener  HC, Sacco  RL,  et al; PRoFESS Study Group.  Telmisartan to prevent recurrent stroke and cardiovascular events.  N Engl J Med. 2008;359(12):1225-1237.PubMedGoogle ScholarCrossref
31.
MacMahon  S, Neal  B, Tzourio  C,  et al; PROGRESS Collaborative Group.  Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack.  Lancet. 2001;358(9287):1033-1041.PubMedGoogle ScholarCrossref
32.
Benavente  OR, Coffey  CS, Conwit  R,  et al; SPS3 Study Group.  Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial.  Lancet. 2013;382(9891):507-515.PubMedGoogle ScholarCrossref
33.
Eriksson  S, Olofsson  BO, Wester  PO.  Atenolol in secondary prevention after stroke.  Cerebrovasc Dis. 1995;5(1):21-25.Google ScholarCrossref
34.
Wright  JT  Jr, Bakris  G, Greene  T,  et al; African American Study of Kidney Disease and Hypertension Study Group.  Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.  JAMA. 2002;288(19):2421-2431.PubMedGoogle ScholarCrossref
35.
Estacio  RO, Jeffers  BW, Gifford  N, Schrier  RW.  Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes.  Diabetes Care. 2000;23(suppl 2):B54-B64.PubMedGoogle Scholar
36.
Hedblad  B, Wikstrand  J, Janzon  L, Wedel  H, Berglund  G.  Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the β-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS).  Circulation. 2001;103(13):1721-1726.PubMedGoogle ScholarCrossref
37.
MacMahon  S, Sharpe  N, Gamble  G,  et al; PART-2 Collaborative Research Group.  Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril.  J Am Coll Cardiol. 2000;36(2):438-443.PubMedGoogle ScholarCrossref
38.
Cornell  JE, Mulrow  CD, Localio  R,  et al.  Random-effects meta-analysis of inconsistent effects: a time for change.  Ann Intern Med. 2014;160(4):267-270.PubMedGoogle ScholarCrossref
39.
Sterne  JA, Sutton  AJ, Ioannidis  JP,  et al.  Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials.  BMJ. 2011;343:d4002.PubMedGoogle ScholarCrossref
40.
Egger  M, Davey Smith  G, Schneider  M, Minder  C.  Bias in meta-analysis detected by a simple, graphical test.  BMJ. 1997;315(7109):629-634.PubMedGoogle ScholarCrossref
41.
Harbord  RM, Egger  M, Sterne  JA.  A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints.  Stat Med. 2006;25(20):3443-3457.PubMedGoogle ScholarCrossref
42.
Schrier  RW, Estacio  RO, Esler  A, Mehler  P.  Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes.  Kidney Int. 2002;61(3):1086-1097.PubMedGoogle ScholarCrossref
43.
Cushman  WC, Evans  GW, Byington  RP,  et al; ACCORD Study Group.  Effects of intensive blood-pressure control in type 2 diabetes mellitus.  N Engl J Med. 2010;362(17):1575-1585.PubMedGoogle ScholarCrossref
44.
Yusuf  S, Healey  JS, Pogue  J,  et al; ACTIVE I Investigators.  Irbesartan in patients with atrial fibrillation.  N Engl J Med. 2011;364(10):928-938.PubMedGoogle ScholarCrossref
45.
Patel  A, MacMahon  S, Chalmers  J,  et al; ADVANCE Collaborative Group.  Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.  Lancet. 2007;370(9590):829-840.PubMedGoogle ScholarCrossref
46.
Maschio  G, Alberti  D, Janin  G,  et al; The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group.  Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency.  N Engl J Med. 1996;334(15):939-945.PubMedGoogle ScholarCrossref
47.
Parving  HH, Brenner  BM, McMurray  JJV,  et al; ALTITUDE Investigators.  Cardiorenal end points in a trial of aliskiren for type 2 diabetes.  N Engl J Med. 2012;367(23):2204-2213.PubMedGoogle ScholarCrossref
48.
 The Australian therapeutic trial in mild hypertension. Report by the Management Committee.  Lancet. 1980;1(8181):1261-1267.PubMedGoogle Scholar
49.
Hansson  L.  The BBB Study: the effect of intensified antihypertensive treatment on the level of blood pressure, side-effects, morbidity and mortality in "well-treated" hypertensive patients: Behandla Blodtryck Bättre.  Blood Press. 1994;3(4):248-254. PubMedGoogle ScholarCrossref
50.
Ruggenenti  P, Fassi  A, Ilieva  AP,  et al; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators.  Preventing microalbuminuria in type 2 diabetes.  N Engl J Med. 2004;351(19):1941-1951.PubMedGoogle ScholarCrossref
51.
Ruggenenti  P, Fassi  A, Ilieva  A,  et al; BENEDICT-B Study Investigators.  Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial.  J Hypertens. 2011;29(2):207-216.PubMedGoogle ScholarCrossref
52.
Verdecchia  P, Staessen  JA, Angeli  F,  et al; Cardio-Sis investigators.  Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial.  Lancet. 2009;374(9689):525-533.PubMedGoogle ScholarCrossref
53.
Ruggenenti  P, Lauria  G, Iliev  IP,  et al; DEMAND Study Investigators.  Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial.  Hypertension. 2011;58(5):776-783.PubMedGoogle ScholarCrossref
54.
Marre  M, Lievre  M, Chatellier  G, Mann  JF, Passa  P, Ménard  J; DIABHYCAR Study Investigators.  Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study).  BMJ. 2004;328(7438):495-499.PubMedGoogle ScholarCrossref
55.
Bosch  J, Yusuf  S, Gerstein  HC,  et al; DREAM Trial Investigators.  Effect of ramipril on the incidence of diabetes.  N Engl J Med. 2006;355(15):1551-1562.PubMedGoogle ScholarCrossref
56.
Liu  L, Zhang  Y, Liu  G, Li  W, Zhang  X, Zanchetti  A; FEVER Study Group.  The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients.  J Hypertens. 2005;23(12):2157-2172.PubMedGoogle ScholarCrossref
57.
Fogari  R, Preti  P, Zoppi  A,  et al.  Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients.  Am J Hypertens. 2002;15(12):1042-1049.PubMedGoogle ScholarCrossref
58.
Coope  J, Warrender  TS.  Randomised trial of treatment of hypertension in elderly patients in primary care.  BMJ (Clin Res Ed). 1986;293(6555):1145-1151. Clin Res Ed.PubMedGoogle ScholarCrossref
59.
Asayama  K, Ohkubo  T, Metoki  H,  et al; Hypertension Objective Treatment Based on Measurement by Electrical Devices of Blood Pressure (HOMED-BP).  Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure.  Hypertens Res. 2012;35(11):1102-1110.PubMedGoogle ScholarCrossref
60.
Lonn  EM, Bosch  J, López-Jaramillo  P,  et al; HOPE-3 Investigators.  Blood-pressure lowering in intermediate-risk persons without cardiovascular disease.  N Engl J Med. 2016;374(21):2009-2020.PubMedGoogle ScholarCrossref
61.
Hansson  L, Zanchetti  A, Carruthers  SG,  et al; HOT Study Group.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial.  Lancet. 1998;351(9118):1755-1762.PubMedGoogle ScholarCrossref
62.
Beckett  NS, Peters  R, Fletcher  AE,  et al; HYVET Study Group.  Treatment of hypertension in patients 80 years of age or older.  N Engl J Med. 2008;358(18):1887-1898.PubMedGoogle ScholarCrossref
63.
Bulpitt  CJ, Beckett  NS, Cooke  J,  et al; Hypertension in the Very Elderly Trial Working Group.  Results of the pilot study for the Hypertension in the Very Elderly Trial.  J Hypertens. 2003;21(12):2409-2417.PubMedGoogle ScholarCrossref
64.
Lewis  EJ, Hunsicker  LG, Clarke  WR,  et al; Collaborative Study Group.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.  N Engl J Med. 2001;345(12):851-860.PubMedGoogle ScholarCrossref
65.
The IPPPSH Collaborative Group.  Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH).  J Hypertens. 1985;3(4):379-392.PubMedGoogle ScholarCrossref
66.
Parving  HH, Lehnert  H, Bröchner-Mortensen  J, Gomis  R, Andersen  S, Arner  P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.  N Engl J Med. 2001;345(12):870-878.PubMedGoogle ScholarCrossref
67.
JATOS Study Group.  Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS).  Hypertens Res. 2008;31(12):2115-2127.PubMedGoogle ScholarCrossref
68.
Lewis  EJ, Hunsicker  LG, Bain  RP, Rohde  RD; The Collaborative Study Group.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.  N Engl J Med. 1993;329(20):1456-1462.PubMedGoogle ScholarCrossref
69.
Medical Research Council Working Party.  MRC trial of treatment of mild hypertension: principal results.  BMJ (Clin Res Ed). 1985;291(6488):97-104. Clin Res Ed.PubMedGoogle ScholarCrossref
70.
MRC Working Party.  Medical Research Council trial of treatment of hypertension in older adults: principal results.  BMJ. 1992;304(6824):405-412.PubMedGoogle ScholarCrossref
71.
McMurray  JJ, Holman  RR, Haffner  SM,  et al; NAVIGATOR Study Group.  Effect of valsartan on the incidence of diabetes and cardiovascular events.  N Engl J Med. 2010;362(16):1477-1490.PubMedGoogle ScholarCrossref
72.
Imai  E, Chan  JCN, Ito  S,  et al; ORIENT study investigators.  Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study.  Diabetologia. 2011;54(12):2978-2986.PubMedGoogle ScholarCrossref
73.
Helgeland  A.  Treatment of mild hypertension: a five year controlled drug trial. The Oslo study.  Am J Med. 1980;69(5):725-732.PubMedGoogle ScholarCrossref
74.
Lüders  S, Schrader  J, Berger  J,  et al; PHARAO Study Group.  The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League.  J Hypertens. 2008;26(7):1487-1496.PubMedGoogle ScholarCrossref
75.
Asselbergs  FW, Diercks  GF, Hillege  HL,  et al; Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators.  Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria.  Circulation. 2004;110(18):2809-2816.PubMedGoogle ScholarCrossref
76.
Fuchs  SC, Poli-de-Figueiredo  CE, Figueiredo Neto  JA,  et al.  Effectiveness of chlorthalidone plus amiloride for the prevention of hypertension: the PREVER-Prevention randomized clinical trial.  J Am Heart Assoc. 2016;5(12):e004248.PubMedGoogle ScholarCrossref
77.
Mauer  M, Zinman  B, Gardiner  R,  et al.  Renal and retinal effects of enalapril and losartan in type 1 diabetes.  N Engl J Med. 2009;361(1):40-51.PubMedGoogle ScholarCrossref
78.
Ravid  M, Brosh  D, Levi  Z, Bar-Dayan  Y, Ravid  D, Rachmani  R.  Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial.  Ann Intern Med. 1998;128(12 Pt 1):982-988.PubMedGoogle ScholarCrossref
79.
Brenner  BM, Cooper  ME, de Zeeuw  D,  et al; RENAAL Study Investigators.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.  N Engl J Med. 2001;345(12):861-869.PubMedGoogle ScholarCrossref
80.
Haller  H, Ito  S, Izzo  JL  Jr,  et al; ROADMAP Trial Investigators.  Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.  N Engl J Med. 2011;364(10):907-917.PubMedGoogle ScholarCrossref
81.
Lithell  H, Hansson  L, Skoog  I,  et al; SCOPE Study Group.  The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial.  J Hypertens. 2003;21(5):875-886.PubMedGoogle ScholarCrossref
82.
SHEP Cooperative Research Group.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP).  JAMA. 1991;265(24):3255-3264.PubMedGoogle ScholarCrossref
83.
Perry  HM  Jr, Smith  WM, McDonald  RH,  et al.  Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) pilot study.  Stroke. 1989;20(1):4-13.PubMedGoogle ScholarCrossref
84.
Wei  Y, Jin  Z, Shen  G,  et al.  Effects of intensive antihypertensive treatment on Chinese hypertensive patients older than 70 years.  J Clin Hypertens (Greenwich). 2013;15(6):420-427.PubMedGoogle ScholarCrossref
85.
Rouleau  JL, Warnica  WJ, Baillot  R,  et al; IMAGINE (Ischemia Management with Accupril post-bypass Graft via Inhibition of the coNverting Enzyme) Investigators.  Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery.  Circulation. 2008;117(1):24-31.PubMedGoogle ScholarCrossref
86.
The MACB Study Group.  Effect of metoprolol on death and cardiac events during a 2-year period after coronary artery bypass grafting.  Eur Heart J. 1995;16(12):1825-1832.PubMedGoogle Scholar
87.
Pitt  B, O’Neill  B, Feldman  R,  et al; QUIET Study Group.  The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function.  Am J Cardiol. 2001;87(9):1058-1063.PubMedGoogle ScholarCrossref
88.
Dahlöf  B, Lindholm  LH, Hansson  L, Scherstén  B, Ekbom  T, Wester  PO.  Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension).  Lancet. 1991;338(8778):1281-1285.PubMedGoogle ScholarCrossref
89.
Staessen  JA, Fagard  R, Thijs  L,  et al; The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension.  Lancet. 1997;350(9080):757-764.PubMedGoogle ScholarCrossref
90.
Neaton  JD, Grimm  RH  Jr, Prineas  RJ,  et al; Treatment of Mild Hypertension Study Research Group.  Treatment of Mild Hypertension Study. Final results.  JAMA. 1993;270(6):713-724.PubMedGoogle ScholarCrossref
91.
UK Prospective Diabetes Study Group.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38.  BMJ. 1998;317(7160):703-713.PubMedGoogle ScholarCrossref
92.
Fried  LF, Emanuele  N, Zhang  JH,  et al; VA NEPHRON-D Investigators.  Combined angiotensin inhibition for the treatment of diabetic nephropathy.  N Engl J Med. 2013;369(20):1892-1903.PubMedGoogle ScholarCrossref
93.
Veterans Administration Cooperative Study Group on Antihypertensive Agents.  Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg.  JAMA. 1970;213(7):1143-1152.PubMedGoogle ScholarCrossref
94.
Ogihara  T, Saruta  T, Rakugi  H,  et al; Valsartan in Elderly Isolated Systolic Hypertension Study Group.  Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study.  Hypertension. 2010;56(2):196-202.PubMedGoogle ScholarCrossref
95.
Yusuf  S, Bosch  J, Dagenais  G,  et al; HOPE-3 Investigators.  Cholesterol lowering in intermediate-risk persons without cardiovascular disease.  N Engl J Med. 2016;374(21):2021-2031.PubMedGoogle ScholarCrossref
96.
Bundy  JD, Li  C, Stuchlik  P,  et al.  Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis.  JAMA Cardiol. 2017;2(7):775-781. doi:10.1001/jamacardio.2017.1421PubMedGoogle ScholarCrossref
97.
Xie  X, Atkins  E, Lv  J,  et al.  Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis.  Lancet. 2016;387(10017):435-443.PubMedGoogle ScholarCrossref
98.
Thomopoulos  C, Parati  G, Zanchetti  A.  Effects of blood pressure lowering on outcome incidence in hypertension, 7: effects of more vs less intensive blood pressure lowering and different achieved blood pressure levels—updated overview and meta-analyses of randomized trials.  J Hypertens. 2016;34(4):613-622.PubMedGoogle ScholarCrossref
99.
Lundh  A, Lexchin  J, Mintzes  B, Schroll  JB, Bero  L.  Industry sponsorship and research outcome.  Cochrane Database Syst Rev. 2017;2(2):MR000033.PubMedGoogle Scholar
100.
Benjamin  EJ, Blaha  MJ, Chiuve  SE,  et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee.  Heart disease and stroke statistics—2017 update: a report from the American Heart Association.  Circulation. 2017;135(10):e146-e603.PubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right

Name Your Search

Save Search
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Topics
State Requirements